| Nombre del producto |
Aducto de grayanotoxina III hemi (acetato de etilo)* |
| Sinónimos |
Grayanotoxina III;Andromedol; BRN 2059374; Deacetillandromedotoxina; Deacilasebotoxina I;Grayanotoxane-3,5,6,10,14,16-hexol, (3-beta,6-beta,14R)-; NSC 323778; (3beta,6beta,14R)-Grayanotoxane-3,5,6,10,14,16-hexol; 7,9a-Methano-9aH-ciclopenta(b)heptaleno-2,4,8,11,11a,12(1H)-hexol, dodecahidro-1,1,4,8-tetrametil-, (2S,3as,4R,4ar,7R,8R,9as,11R,11aR,12R)-; Grayanotoxane-3,5,6,10,14,16-hexol, (3beta,6beta,14R)- (9CI); grayanotoxane-3,5,6,10,14,16-hexol; (1beta, 3 alfa, 5 alfa, 6 alfa, 8 beta, 9 alfa, 10 alfa, 13 beta, 14S) -grayanotoxane-3,5,6,10,14,16-hexol; (3beta,6beta)-grayanotoxane-3,5,6,10,14,16-hexol |
| Nombre en inglés |
grayanotoxin iii hemi(ethyl acetate)*adduct;Grayanotoxin III; Andromedol; BRN 2059374; Deacetylandromedotoxin; Deacylasebotoxin I; Grayanotoxane-3,5,6,10,14,16-hexol, (3-beta,6-beta,14R)-; NSC 323778; (3beta,6beta,14R)-Grayanotoxane-3,5,6,10,14,16-hexol; 7,9a-Methano-9aH-cyclopenta(b)heptalene-2,4,8,11,11a,12(1H)-hexol, dodecahydro-1,1,4,8-tetramethyl-, (2S,3as,4R,4ar,7R,8R,9as,11R,11aR,12R)-; Grayanotoxane-3,5,6,10,14,16-hexol, (3beta,6beta,14R)- (9CI); grayanotoxane-3,5,6,10,14,16-hexol; (1beta,3alpha,5alpha,6alpha,8beta,9alpha,10alpha,13beta,14S)-grayanotoxane-3,5,6,10,14,16-hexol; (3beta,6beta)-grayanotoxane-3,5,6,10,14,16-hexol |
| Fórmula molecular |
C20H34O6 |
| Peso Molecular |
370.4804 |
| InChI |
InChI=1/C20H34O6/c1-16(2)13(21)7-12-18(4,25)11-6-5-10-15(23)19(11,9-17(10,3)24)8-14(22)20(12,16)26/h10-15,21-26H,5-9H2,1-4H3/t10?,11-,12-,13-,14+,15?,17+,18+,19-,20-/m0/s1 |
| Número de registro CAS |
4678-45-9 |
| Estructura Molecular |
|
| Densidad |
1.36g/cm3 |
| Punto de ebullición |
552.6°C at 760 mmHg |
| Índice de refracción |
1.619 |
| Punto de inflamación |
250.9°C |
| Presión de vapor |
1.63E-14mmHg at 25°C |
| Símbolos de Peligro |
|
| Códigos de Riesgos |
|
| Descripción de Seguridad |
|
|
